Global Expansion And Decentralized Testing Will Unlock Future Potential

QuidelOrtho's analyst price target has been lowered from $40.33 to $37.67. This reflects adjustments to discount rates and margin forecasts as analysts re-evaluate the company's outlook.

Analysts have modestly reduced their price targets for QuidelOrtho to $40.33, reflecting a cautious outlook despite solid quarterly results and prudent guidance, as the market awaits further proof of sustainable performance. Analyst Commentary Revenues for the quarter were roughly in line with estimates, with Labs outperforming expectations and respiratory revenues meeting expectations.

The consensus analyst price target for QuidelOrtho has been revised downward, primarily reflecting a sharp deterioration in profitability—evidenced by a collapse in net profit margin and a spike in the future P/E ratio—with fair value lowered from $47.14 to $43.57. What's in the News QuidelOrtho reiterated its full year 2025 earnings guidance, with expected revenues between $2.60 billion and $2.81 billion.

AnalystConsensusTarget has decreased profit margin from 12.9% to 2.6% and increased future PE multiple from 12.1x to 59.0x.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has increased revenue growth from 1.9% to 2.1%.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.